CHIARINI, Francesca
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 5.366
NA - Nord America 4.755
EU - Europa 2.071
SA - Sud America 753
AF - Africa 71
OC - Oceania 5
Continente sconosciuto - Info sul continente non disponibili 1
Totale 13.022
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.630
CN - Cina 1.916
SG - Singapore 1.748
BR - Brasile 581
IT - Italia 540
HK - Hong Kong 506
VN - Vietnam 390
GB - Regno Unito 366
KR - Corea 328
FI - Finlandia 252
SE - Svezia 189
RU - Federazione Russa 166
DE - Germania 137
FR - Francia 129
BD - Bangladesh 108
ID - Indonesia 82
AR - Argentina 68
IN - India 63
NL - Olanda 60
LT - Lituania 56
CA - Canada 49
MX - Messico 45
IQ - Iraq 35
IE - Irlanda 34
EC - Ecuador 33
JP - Giappone 29
TR - Turchia 26
AT - Austria 24
UA - Ucraina 23
ZA - Sudafrica 21
PL - Polonia 19
PK - Pakistan 17
AE - Emirati Arabi Uniti 15
PY - Paraguay 14
VE - Venezuela 14
ES - Italia 13
CL - Cile 12
KE - Kenya 12
CO - Colombia 11
CZ - Repubblica Ceca 10
UZ - Uzbekistan 10
IL - Israele 9
MA - Marocco 9
PE - Perù 9
SA - Arabia Saudita 9
NP - Nepal 8
TH - Thailandia 8
TN - Tunisia 7
UY - Uruguay 7
MY - Malesia 6
OM - Oman 6
PT - Portogallo 6
AL - Albania 5
CG - Congo 5
CR - Costa Rica 5
DO - Repubblica Dominicana 5
GT - Guatemala 5
PA - Panama 5
PH - Filippine 5
RO - Romania 5
AU - Australia 4
BG - Bulgaria 4
BO - Bolivia 4
DZ - Algeria 4
EG - Egitto 4
LK - Sri Lanka 4
PS - Palestinian Territory 4
SK - Slovacchia (Repubblica Slovacca) 4
AZ - Azerbaigian 3
BA - Bosnia-Erzegovina 3
CH - Svizzera 3
JM - Giamaica 3
KG - Kirghizistan 3
LA - Repubblica Popolare Democratica del Laos 3
LB - Libano 3
LV - Lettonia 3
MD - Moldavia 3
RS - Serbia 3
SY - Repubblica araba siriana 3
TW - Taiwan 3
AM - Armenia 2
BE - Belgio 2
BH - Bahrain 2
BY - Bielorussia 2
DK - Danimarca 2
ET - Etiopia 2
IR - Iran 2
JO - Giordania 2
KZ - Kazakistan 2
NG - Nigeria 2
NI - Nicaragua 2
NO - Norvegia 2
PR - Porto Rico 2
QA - Qatar 2
SN - Senegal 2
A2 - ???statistics.table.value.countryCode.A2??? 1
BN - Brunei Darussalam 1
CI - Costa d'Avorio 1
EE - Estonia 1
GE - Georgia 1
Totale 13.008
Salva come PNG Salva come JPEG
Città #
Hefei 1.197
Santa Clara 1.068
Singapore 933
Ashburn 756
San Jose 565
Hong Kong 500
Seoul 328
Dallas 299
Helsinki 229
London 215
Council Bluffs 199
The Dalles 154
Beijing 146
Nyköping 140
Los Angeles 120
Ho Chi Minh City 118
Hanoi 108
Milan 84
Chicago 80
Lauterbourg 75
Shanghai 74
Kent 70
Jakarta 64
Buffalo 60
Munich 58
Fairfield 54
Moscow 53
Chandler 50
New York 47
São Paulo 45
Boardman 43
Houston 43
Bologna 36
Dublin 33
Woodbridge 32
Southend 30
Parma 29
Amsterdam 28
Frankfurt am Main 28
Modena 27
Tampa 25
Porto Alegre 24
Redondo Beach 24
Rome 24
Salt Lake City 24
Cambridge 23
Nuremberg 21
Atlanta 20
Tokyo 20
Guangzhou 18
Rio de Janeiro 18
Seattle 18
Wilmington 18
Orem 17
Brasília 16
Reggio Emilia 16
Baghdad 15
Columbus 15
Haiphong 15
Indianapolis 15
Mexico City 15
Miano 15
Washington 15
Chennai 14
Da Nang 14
Phoenix 14
Warsaw 13
Stockholm 12
Belo Horizonte 11
Brooklyn 11
Kilburn 11
Lancaster 11
Lappeenranta 11
Montreal 11
Nairobi 11
Paris 11
Quito 11
Turku 11
Elk Grove Village 10
Tashkent 10
Vienna 10
Boston 9
Chiswick 9
Curitiba 9
Dhaka 9
Erbil 9
Naples 9
Padova 9
Poplar 9
San Diego 9
Tianjin 9
Vancouver 9
Ann Arbor 8
Assago 8
Campinas 8
Denver 8
Guayaquil 8
Hillsboro 8
Islington 8
Johannesburg 8
Totale 9.019
Salva come PNG Salva come JPEG
Nome #
Dual inhibition of PI3K/mTOR signaling in chemoresistant AMLprimary cells. 316
Lamin A and the LINC complex act as potential tumor suppressors in Ewing Sarcoma 272
Crosstalks of GSK3 signaling with the mTOR network and effects on targeted therapy of cancer 257
Antigene MYCN Silencing by BGA002 Inhibits SCLC Progression Blocking mTOR Pathway and Overcomes Multidrug Resistance 254
Synergistic cytotoxic effects of bortezomib and CK2 inhibitor CX-4945 in acute lymphoblastic leukemia: Turning offthe prosurvival ER chaperone BIP/Grp78 and turning on the proapoptotic NF-κB 214
Assessment of the structural and functional characteristics of human mesenchymal stem cells associated with a prolonged exposure of morphine 182
A combination of temsirolimus, an allosteric mTOR inhibitor, with clofarabine as a new therapeutic option for patients with acute myeloid leukemia 179
Molecular Signature of Biological Aggressiveness in Clear Cell Sarcoma of the Kidney (CCSK) 177
A COMBINATION OF BORTEZOMIB WITH CX-4945, A CASEIN KINASE 2 (CK2) INHIBITOR, HAS SYNERGISTIC CYTOTOXIC EFFECTS IN ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) CELL LINES 174
B-ALL Complexity: Is Targeted Therapy Still A Valuable Approach for Pediatric Patients? 174
Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235, against T-cell acute lymphoblastic leukemia 171
Effect of Erythropoietin Treatment on Lipid Signalling Pathways in Low-Risk MDS Patients 170
Alteration of Akt activity increases chemotherapeutic drug and hormonal resistance in breast cancer yet confers an achilles heel by sensitization to targeted therapy 170
Pathobiology and Therapeutic Relevance of GSK-3 in Chronic Hematological Malignancies 166
Cytotoxic activity of the casein kinase 2 inhibitor CX-4945 against T-cell acute lymphoblastic leukemia: targeting the unfolded protein response signaling 163
Advances in understanding the acute lymphoblastic leukemia bone marrow microenvironment: From biology to therapeutic targeting 163
Synergistic induction of PI-PLCbeta1 signaling by azacitidine and valproic acid in high-risk myelodysplastic syndromes 162
Preclinical testing of the Akt inhibitor triciribine in T-cell acute lymphoblastic leukemia 161
Age-Related Alterations Affecting the Chondrogenic Differentiation of Synovial Fluid Mesenchymal Stromal Cells in an Equine Model 159
ASSESSMENT OF THE EFFECT OF SPHINGOSINE KINASE INHIBITORS ON APOPTOSIS, UNFOLDED PROTEIN RESPONSE AND AUTOPHAGY OF T-ACUTE LYMPHOBLASTIC LEUKEMIA CELLS: INDICATIONS FOR NOVEL THERAPEUTICS 159
Activity of the pan-class I phosphoinositide 3-kinase inhibitor NVP-BKM120 in T-cell acute lymphoblastic leukemia 155
Cellular senescence in vascular wall mesenchymal stromal cells, a possible contribution to the development of aortic aneurysm 154
Assessment of the effect of sphingosine kinase inhibitors on apoptosis,unfolded protein response and autophagy of T-cell acute lymphoblastic leukemia cells; indications for novel therapeutics 153
Lamin A and Prelamin A Counteract Migration of Osteosarcoma Cells 150
AMP-dependent kinase/mammalian target of rapamycin complex 1 signaling in T-cell acute lymphoblastic leukemia: therapeutic implications 150
Activity of the selective IκB kinase inhibitor BMS-345541 against T-cell acute lymphoblastic leukemia: involvement of FOXO3a 147
The Role Played by Wnt/β-Catenin Signaling Pathway in Acute Lymphoblastic Leukemia 146
13. PLCβ1a and PLCβ1b selective regulation and cyclin D3 modulation reduced by kinamycin F during k562 cell differentiation 146
Synergistic proapoptotic activity of recombinant TRAIL plus the Akt inhibitor perifosine in acute myeloid leukemia cells 146
At the Nucleus of Cancer – How the Nuclear Envelope Controls Tumor Progression 144
A role of PI-PLCb1 in G1/S transition in human erythroleukemia k562 cells 142
Advances in understanding the mechanisms of evasive and innate resistance to mTOR inhibition in cancer cells 141
Targeting metabolic vulnerabilities and aberrant signal transduction pathways in paediatric T-cell Acute Lymphoblastic Leukaemia (T-ALL) 140
Reduction of phosphoinositide-phospholipase C beta1 methylation predicts the responsiveness to azacitidine in high-risk MDS 139
Therapeutic targeting of CK2 in acute and chronic leukemias 137
Involvement of nuclear PLC{beta}1 in lamin B1 phosphorylation and G2/M cell cycle progression 137
Targeting Wnt/β-catenin and PI3K/Akt/mTOR pathways in T-cell acute lymphoblastic leukemia 136
GSK-3: a multifaceted player in acute leukemias 136
Targeted inhibition of mTORC1 and mTORC2 by active-site mTOR inhibitors has cytotoxic effects in T-cell acute lymphoblastic leukemia 135
Therapeutic potential of targeting sphingosine kinases and sphingosine 1-phosphate in hematological malignancies 134
The Combination of AHCC and ETAS Decreases Migration of Colorectal Cancer Cells, and Reduces the Expression of LGR5 and Notch1 Genes in Cancer Stem Cells: A Novel Potential Approach for Integrative Medicine 134
The Akt/mammalian target of rapamycin signal transduction pathway is activated in high-risk myelodysplastic syndromes and influences cell survival and proliferation 132
Temsirolimus, an mTOR inhibitor, in combination with lower-dose clofarabine as salvage therapy for older patients with acute myeloid leukaemia: results of a phase II GIMEMA study (AML-1107) 132
Targeting the phosphatidylinositol 3-kinase/Akt/mTOR signaling network in acute myelogenous leukaemia 131
New advances in targeting aberrant signaling pathways in T-cell acute lymphoblastic leukemia 130
Improving nelarabine efficacy in T cell acute lymphoblastic leukemia by targeting aberrant PI3K/AKT/mTOR signaling pathway 129
Magnesium and strontium-enriched bioactive glasses: superior biocompatibility and angiogenesis, beyond the gold standard 129
Toxicity of antimony trioxide nanoparticles on human hematopoietic progenitor cells and comparison to cell lines 128
Targeting the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin module for acute myelogenous leukemia therapy: from bench to bedside 128
Autophagy in acute leukemias: a double-edged sword with important therapeutic implications 128
Harnessing the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia: eliminating activity by targeting at different levels 127
The Cutting Edge: The Role of mTOR Signaling in Laminopathies 127
Temsirolimus, An Allosteric mTORC1 Inhibitor, Is Synergistic with Clofarabine in AML and AML Leukemia Initiating Cells 125
Surface Charge Overrides Protein Corona Formation in Determining the Cytotoxicity, Cellular Uptake, and Biodistribution of Silver Nanoparticles 124
Effect of Lenalidomide Treatment on Lipid Signalling Pathways in Low-Risk MDS Patients 124
Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response 123
Current treatment strategies for inhibiting mTOR in cancer 122
Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor (2S)-1-(1H-Indol-3-yl)-3-[5-(3-methyl-2H-indazol-5-yl)pyridin-3-yl]oxypropan2-ami ne (A443654) in T-cell acute lymphoblastic leukemia 122
Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor perifosine in acute myelogenous leukemia cells 121
Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment 121
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascade Inhibitors: How Mutations Can Result in Therapy Resistance and How to Overcome Resistance 120
K562 cell proliferation is modulated by PLCβ1 through a PKCα-mediated pathway 117
Differential Cytotoxicity of Surface-Functionalized Silver Nanoparticles in Colorectal Cancer and Ex-Vivo Healthy Colonocyte Models 115
Erucylphosphohomocholine, the first intravenously applicable alkylphosphocholine, is cytotoxic to acute myelogenous leukemia cells through JNK- and PP2A-dependent mechanisms 114
Cytotoxic activity of the novel Akt inhibitor, MK-2206, in T-cell acute lymphoblastic leukemia 113
Implication of Cellular Senescence in Osteoarthritis: A Study on Equine Synovial Fluid Mesenchymal Stromal Cells 112
Targeting the liver kinase B1/AMP-activated protein kinase pathway as a therapeutic strategy for hematological malignancies 112
MYCN is a novel oncogenic target in pediatric T-cell acute lymphoblastic leukemia 111
Understanding the Roles of the Hedgehog Signaling Pathway during T-Cell Lymphopoiesis and in T-Cell Acute Lymphoblastic Leukemia (T-ALL) 111
Dual inhibition of class IA phoshatidylinositol 3-kinase and mTOR as a new therapeutic option for T-cell acute lymphoblastic leukemia 110
Targeting Signaling Pathways in T-cell acute lymphoblastic leukemia initiating cells 110
The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients 110
The unfolded protein response: a novel therapeutic target in acute leukemias 109
Inhibition of Methyltransferase DOT1L Sensitizes to Sorafenib Treatment AML Cells Irrespective of MLL-Rearrangements: A Novel Therapeutic Strategy for Pediatric AML 108
Hh/Gli antagonist in acute myeloid leukemia with CBFA2T3-GLIS2 fusion gene 108
PI3K pan-inhibition impairs more efficiently proliferation and survival of T-cell acute lymphoblastic leukemia cell lines when compared to isoform-selective PI3K inhibitors 108
Therapeutic Targeting of mTOR in T-Cell Acute Lymphoblastic Leukemia: An Update 104
The Emerging Role of the Phosphatidylinositol 3-Kinase/Akt/Mammalian Target of Rapamycin Signaling Network in Cancer Stem Cell Biology 104
Therapeutic targeting of Polo-like kinase-1 and Aurora kinases in T-cell acute lymphoblastic leukemia 103
Increased NGAL (Lnc2) expression after chemotherapeutic drug treatment 103
Enhancing the effectiveness of nucleoside analogs with mTORC1 blockers to treat acute myeloid leukemia patients 103
The cyclin-dependent kinase inhibitor roscovitine and the nucleoside analog sangivamycin induce apoptosis in caspase-3 deficient breast cancer cells independent of caspase mediated P-glycoprotein cleavage 100
The novel Akt inhibitor, perifosine, induces caspase-dependent apoptosis and downregulates P-glycoprotein expression in multidrug-resisten human T-acute leukemia cells by a JNK-dependent mechanism 98
Lamin A acts a tumor suppressor in Ewing sarcoma promoting neural differentiation and reducing cell migration and invasion 95
Therapeutic potential of targeting mTOR in T-cell acute lymphoblastic leukemia (Review) 95
Pediatric early T-cell precursor leukemia with NF1 deletion and high-sensitivity in vitro to tipifarnib 94
Dual Inhibition of Phosphatidylinositol 3-Kinase and Mammalian Target of Rapamycin: a Therapeutic Strategy for Acute Leukemias 92
Targeting phosphatidylinositol 3-kinase signaling in acute myelogenous leukemia 90
Phosphatidylinositol 3-kinase inhibition potentiates glucocorticoid response in B-cell acute lymphoblastic leukemia 88
Phospholipase C-β1 interacts with cyclin E in adipose- derived stem cells osteogenic differentiation 88
C033 Quantification of phosphoinositidephospholipase C (PI-PLC) beta 1 gene promoter methylation predicts the responsiveness to azacitidine in myelodysplastic syndromes 86
PI3K/AKT/mTORC1 and MEK/ERK signaling in T-cell acute lymphoblastic leukemia: new options for targeted therapy 86
The phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin signaling network and the control of normal myelopoiesis 85
Expression of a functional CCR7 chemokine receptor inhibits the post-intravasation steps of metastasis in malignant murine mammary cancer cells 85
C025 Role of lipid signaling pathways in the response to erythropoietin in low risk MDS patients 84
The emerging role of the phosphatidylinositol 3-kinase/Akt/mTOR signaling network in normal myelopoieis and leukemogenesis 80
Development and 3D Printing of AESO-Based Composites Containing Olive Pit Powder 58
New agents and approaches for targeting the RAS/RAF/MEK/ERK and PI3K/AKT/mTOR cell survival pathways 52
The Association Between Muscle Strength, Body Cell Mass, and Training Session Hours in Young Female Artistic Gymnasts: A Pilot Study 45
Advances in Targeting Signal Transduction Pathways 6
Totale 13.060
Salva come PNG Salva come JPEG
Categoria #
all - tutte 70.771
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 70.771
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202113 0 0 0 0 0 0 0 0 0 0 0 13
2021/202274 3 6 4 13 2 4 2 6 6 7 13 8
2022/2023514 5 7 11 24 41 66 30 61 94 19 58 98
2023/2024871 35 26 37 145 120 64 173 60 20 28 86 77
2024/20253.810 83 19 13 227 848 625 109 143 385 125 608 625
2025/20267.512 707 634 1.099 876 661 387 864 280 638 654 389 323
Totale 13.060